Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.

The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

The company faces challenges in developing a single-dose shingles vaccine candidate that meets non-inferiority margins compared to Shingrix. Q: With the updated 2030 market view, does the previous ...

GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces to try to grab a slice of ...

which is currently being used in such vaccines as GSK’s Shingrix for shingles, Arexvy for RSV, Novavax’s COVID-19 vaccine, and others. “We’re a pretty new company to the space of vaccine ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Jefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...

Eliminating fake vaccine news with pharmacist, nurse, and physician review.